前列腺癌胚系检测实施:2019费城前列腺癌共识会议
该多学科共识会议针对前列腺癌胚系检测的实施挑战,采用改良Delphi模型形成遗传评估框架。框架推荐转移性前列腺癌采用大panel胚系检测和体细胞检测,并明确BRCA2、BRCA1和错配修复基因等优先检测基因,以及BRCA2携带者从40岁或家族最早诊断前10年开始筛查。
要点
- 转移性前列腺癌推荐大panel胚系检测和体细胞检测。
- 转移性疾病治疗优先检测BRCA2、BRCA1和错配修复基因。
- BRCA2携带者建议从40岁或家族最早诊断前10年开始筛查。
核心结论
- 该多学科共识驱动的前列腺癌遗传实施框架为精准医疗时代的临床医生和患者提供了新指导。
研究设计与样本
- 多学科共识会议纳入专家、利益相关者和国家组织领导人,采用改良Delphi模型进行证据回顾并形成框架。
主要发现
- 转移性前列腺癌推荐大panel胚系检测和体细胞检测。
- 转移性疾病治疗优先检测基因为BRCA2、BRCA1和错配修复基因,ATM等更广泛检测用于临床试验资格。
- BRCA2推荐用于主动监测讨论。
- BRCA2携带者推荐从40岁或家族最早前列腺癌诊断前10年开始筛查,HOXB13、BRCA1、ATM和错配修复携带者可考虑。
- 推荐医疗保健与遗传提供者之间的协作(即时)评估模型以应对遗传咨询短缺。
关键数值与推荐
- 最终框架纳入强 agreement(>75%)的Recommend或中等 agreement(50%至74%)的Consider标准。
临床怎么用
- 转移性前列腺癌患者应接受大panel胚系检测和体细胞检测。
- 转移性疾病治疗前优先检测BRCA2、BRCA1和错配修复基因。
- BRCA2携带者应从40岁或家族最早诊断前10年开始筛查。
- 采用协作评估模型以应对遗传咨询资源不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. METHODS: A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider). RESULTS: Large germline panels and somatic testing were recommended for metastatic PCA. Reflex testing-initial testing of priority genes followed by expanded testing-was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches. CONCLUSION: This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.
引用
- Giri VN, Knudsen KE, Kelly WK, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020. PMID: 32516092. doi:10.1200/JCO.20.00046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。